But Indevus' run of bad luck began long before, when the company had another name entirely.

FORBES: Magazine Article

Like Endo, Indevus focuses not so much on breakthrough science as in putting together a stable of similar medicines.

FORBES: Endo To Buy Indevus

Pagoclone doesn't seem to be working out, but with trospium, Indevus may have a one more shot at comeback.

FORBES: A Biotech Phoenix Could Be Rising

Indevus made a decision to change its business plan, and, later, its name.

FORBES: A Biotech Phoenix Could Be Rising

So-called use patents on the application were sold to Lilly, which continued for a time to provide a modest revenue stream to Indevus.

FORBES: A Biotech Phoenix Could Be Rising

Indevus Pharmaceuticals has had one of the rockiest histories in the biotechnology sector, with big hopes for new drugs being shattered again and again.

FORBES: Magazine Article

In June, Pfizer (nyse: PFE - news - people ) ended its collaboration with Indevus over an anti-anxiety drug called pagoclone.

FORBES: Magazine Article

Indevus was founded as Interneuron , a company based on intellectual property that came out of the laboratory of MIT professor Richard Wurtman .

FORBES: A Biotech Phoenix Could Be Rising

In August, Aventis (nyse: AVE - news - people ), which had originally developed pagoclone and had licensed it to Indevus, decided not to exercise its option to develop the drug.

FORBES: Magazine Article

In a late-stage clinical trial, trospium met all the goals Indevus (nasdaq: IDEV - news - people ) had set for it, reducing urination frequency and the number of times patients lost bladder control.

FORBES: Magazine Article